INS and diabetic kidney disease: The second study by Kojima et al utilized older (> I year old) type 2 diabetic rats with established diabetic nephropathy and showed that although matched for glucose levels the diabetic mice receiving the SGLT2i luseogliflozin had better renal outcomes than the mice receiving insulin.